prevacid rebate offer
BRUSSELS, Belguim, July 24, 2008--Solvay Pharmaceuticals S. A., a subsidiary of Solvay, the chemical and pharmaceutical group, today announced that it plans the offer period to acquire Innogenetics N. V., a Belgian-based biotechnological company, from August 12 to September 5, pending approval of the takeover prospectus by Belgium’s Banking, Finance and Insurance Commission (CBFA). Solvay’s improved offer values the transaction at EUR 6. 50 per share, as stated on July 9, 2008. The proposed transaction is expected to close in the second half of 2008 and is subject to the following closing conditions (unless waived by Solvay): (a) no material adverse change in connection with Innogenetics resulting in a loss exceeding EUR 10 million; and (b) an acceptance threshold of at least 75%. prevacid solutab drug alternative to prevacid over the counter taking prevacid and cost prevacid 2737 aid clarinex prevacid